Tiotropium as an add‑on treatment to inhaled corticosteroids in children with severe and mild symptomatic asthma: Multi‑center observational study for efficacy and safety analysis

• Published in: Experimental and therapeutic medicine 2022-09, Vol.24 (3), Article 577
• Main Authors: Aierken, Aibibai, Fu, Bu Wei Mai Erye Mu Yu Su, Xu, Peiru
• Format: Article
• Language: English
• Subjects: Asthma; Asthma in children; Chronic illnesses; Corticosteroids; Dosage and administration; Drug therapy; Drug therapy, Combination; Immunomodulators; Observational studies; Pediatric research; Pediatrics; Respiratory system; Statistical analysis; Steroids; Testing; Tiotropium
• ISSN: 1792-0981; 1792-1015
• DOI: 10.3892/etm.2022.11514

Children aged 6-11 years with uncontrolled asthma are treated with low-dose inhaled corticosteroid (ICS) with stepwise increase in ICS dosage and/or add-on maintenance treatment, as necessary. The objective of the present study was to evaluate the efficacy and safety of tiotropium add-on treatment in children with severe and mild symptomatic asthma. The present prospective cohort study included 144 children with severe and mild asthma (age, 6-11 years) who received ICS (budesonide) with [greater than or equal to] 1 controller treatment combination therapies for [greater than or equal to] 1 month and score [greater than or equal to] 1.5 based on Asthma Control Questionnaire-Interviewer-Administered. In addition to ICS with [greater than or equal to] 1 controller treatment, children received 5 [micro]g once-daily tiotropium (treatment group; n=72) or did not receive tiotropium (control group; n=72). The peak forced expiratory volume in 1-sec change from the baseline 3 h post-administration of tiotropium was significantly improved in the treatment group compared with the control group (384 [+ or -] 31 vs. 248 [+ or -] 28 ml; P